Response Genetics RGDXQ · USD

Market value

$3,876

Last close × shares

Volume

77k

Shares, 30 Oct 2026

Its shares trade under the ticker RGDXQ. It has been listed since 5 June 2007. In the fiscal year to 31 December 2015, it reported revenue of $18.0m and a net loss of $20.2m. At that date it held total assets of $48.9m and shareholders' equity of $33.0m.

Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. The company is headquartered in Los Angeles, California. The company went IPO on 2007-06-05. The firm is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The firm's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The firm is engaged in selling ResponseDX diagnostic testing products. The firm provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Figures and description from our data supplier, not checked against the company's own report.

More about Response Genetics →

We have not reported on Response Genetics yet.

Leaves out fees, taxes and financing.

Chart

TradingView

Close and company data

Our data supplier

News

Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.